Replies to post #129525 on Biotech Values

[biomaven0]

Well, it was thought JAK3 might have advantage over PFE's pan-JAK in safety

Of course INCY has argued precisely the opposite (given they have a JAK1/2) drug. But I assume they are talking their book.

Peter

[genisi]

Serious AEs occurred in 4.9% of VX-509 and 2.4% of placebo subjects, with serious infection in 3.1% of VX-509 subjects and none in placebo.

And it was only 12 weeks of dosing.